TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Red Wine Polyphenols on Microvascular Dysfunction
Brief Summary: Rationale:

Epidemiological studies have shown that consumption of alcoholic beverages, red wine in particular, is associated with less cardiovascular mortality. In addition, there are reported beneficial effects of red wine on components of the metabolic syndrome, arguably the most menacing cardiometabolic condition facing us due to the unfolding obesity epidemic. Beneficial effects have also been reported with other polyphenol-rich food stuff, such as cocoa and green tea and points to a beneficial effect which does not seem to be dependent on the alcohol content of red wine. Experimental studies with mixed or separate Red Wine Polyphenols (RWPs) (i.e. without alcohol) have shown beneficial effects on cardiometabolic parameters associated with obesity. Most research has focused on resveratrol, a specific polyphenol components which is quite specific to red wine and has, at least in animal studies, beneficial effects on insulin sensitivity, insulin secretion, and endothelial function. Moreover, RWPs have shown to improve endothelial NO-mediated relaxation using the same PI3-kinase/Akt pathway as does insulin. However, data in humans are remarkably scarce

Objective:

To study effects of RWPs on insulin sensitivity, beta-cell function, microvascular function (skin, muscle and cardiac), blood pressure, insulin-mediated microvascular responsiveness.

Study design:

Randomized controlled trial (double blind).

Study population:

Obese (BMI \>30); n=30, men or women, aged 18-60 years.

Intervention:

Mixed RWP 600mg/day or matching placebo for a total duration of 8 weeks.


Options:
A: Arm Label: Red Wine Polyphenols; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Red Wine Polyphenols 600mg/day | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Red Wine Polyphenols 600mg/day; Assigned to Arm(s): Red Wine Polyphenols | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: alcohol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Ethanol-free beverage | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: ethanol | Intervention Type: OTHER; Name: ethanol; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Ethanol-free beverage; Assigned to Arm(s): 1
D: Arm Label: alcohol 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: alcohol | Arm Label: alcohol 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: alcohol | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: alcohol | Intervention Type: DIETARY_SUPPLEMENT; Name: alcohol; Assigned to Arm(s): alcohol 1, alcohol 2, control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Efficacy and Metabolic Impact of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Normal-weight Women With Polycystic Ovary Syndrome: a Randomized Study.
Brief Summary: The estrogenic component of estro-progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).

The objective of this study is to compare the effects of a long term administration of two EP combinations, containing the same progestin (3 mg drospirenone) and a different dose of ethinyl-estradiol (EE) (20 vs 30 μg ) on the clinical and endocrine-metabolic parameters in normal weight PCOS women. The investigators enrolled 30 patients, randomly allocated to group A (20 µg EE - 3 mg DRSP) and 15 to group B (30 µg EE - 3 mg DRSP). Hirsutism score evaluation, hormonal assays, oral glucose tolerance test, euglycaemic hyperinsulinaemic clamp and lipid profile were performed at baseline and after 6 and 12 months of therapy.


Options:
A: Arm Label: Low-frequency electro-acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: Physical exercise; Type: EXPERIMENTAL; Interventions: Procedure: Physical exercise | Arm Label: Untreated control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Untreated control | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): Low-frequency electro-acupuncture | Intervention Type: PROCEDURE; Name: Physical exercise; Assigned to Arm(s): Physical exercise | Intervention Type: PROCEDURE; Name: Untreated control; Assigned to Arm(s): Untreated control
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
D: Arm Label: 3 mg drospirenone and 20 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 20 µg ethinyl-estradiol | Arm Label: 3 mg drospirenone and 30 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 30 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 20 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 20 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 30 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 30 µg ethinyl-estradiol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Title: Comparative Effectiveness of Pedometer-Based Walking Interventions: WalkMore
Brief Summary: The WalkMore study will help find out how walking interventions can help overweight/obese postmenopausal women with increased risk of cardiovascular disease lower their blood pressure.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group mediated cognitive behavioral (GMCB) sessions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions | Intervention Type: BEHAVIORAL; Name: Group mediated cognitive behavioral (GMCB) sessions; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Health education sessions; Assigned to Arm(s): 2
B: Arm Label: Basic Pedometry Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Intervention | Arm Label: Enhanced Pedometry Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Pedometry | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Basic Intervention; Assigned to Arm(s): Basic Pedometry Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Pedometry; Assigned to Arm(s): Enhanced Pedometry Intervention | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Control Group
C: Arm Label: pedometer-plus-email; Type: EXPERIMENTAL; Interventions: Behavioral: pedometer-plus-email | Arm Label: pedometer-only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: pedometer-only | Intervention Type: BEHAVIORAL; Name: pedometer-plus-email; Assigned to Arm(s): pedometer-plus-email | Intervention Type: BEHAVIORAL; Name: pedometer-only; Assigned to Arm(s): pedometer-only
D: Arm Label: Control Group; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Programme Only Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Other: Usual Care | Arm Label: Cash Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Cash Incentives, Other: Usual Care | Arm Label: Charitable Incentive Group; Type: EXPERIMENTAL; Interventions: Device: Fitbit, Behavioral: Charitable Incentives, Other: Usual Care | Intervention Type: DEVICE; Name: Fitbit; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Programme Only Group | Intervention Type: BEHAVIORAL; Name: Cash Incentives; Assigned to Arm(s): Cash Incentive Group | Intervention Type: BEHAVIORAL; Name: Charitable Incentives; Assigned to Arm(s): Charitable Incentive Group | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Cash Incentive Group, Charitable Incentive Group, Control Group, Programme Only Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-stroke Procedural Learning: From Neural Substrates to Therapeutic Modulation by Non-invasive Brain Stimulation
Brief Summary: Noninvasive brain stimulations (NIBS) will be used in chronic stroke patients to improve motor learning.

Functional magnetic resonance imaging will be used to evaluate the mechanisms underlying motor learning in healthy volunteers and in chronic stroke patients.


Options:
A: Arm Label: Real; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Arm Label: sham; Type: PLACEBO_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Intervention Type: DEVICE; Name: transcranial direct current stimulation tDCS; Assigned to Arm(s): Real, sham | Intervention Type: DEVICE; Name: transcranial magnetic stimulation TMS; Assigned to Arm(s): Real, sham
B: Arm Label: real tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: tDCS | Arm Label: no stimulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): real tDCS, sham tDCS
C: Arm Label: tDCS and occupational therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: Sham and occupational therapy; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): tDCS and occupational therapy | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham and occupational therapy
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: physical rehabilitation | Intervention Type: BEHAVIORAL; Name: physical rehabilitation; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-stroke Procedural Learning: From Neural Substrates to Therapeutic Modulation by Non-invasive Brain Stimulation
Brief Summary: Noninvasive brain stimulations (NIBS) will be used in chronic stroke patients to improve motor learning.

Functional magnetic resonance imaging will be used to evaluate the mechanisms underlying motor learning in healthy volunteers and in chronic stroke patients.


Options:
A: Arm Label: Real; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Arm Label: sham; Type: PLACEBO_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Intervention Type: DEVICE; Name: transcranial direct current stimulation tDCS; Assigned to Arm(s): Real, sham | Intervention Type: DEVICE; Name: transcranial magnetic stimulation TMS; Assigned to Arm(s): Real, sham
B: Arm Label: Arm A Anodal tDCS and prismatic adaptation; Type: EXPERIMENTAL; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: Arm B: control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control: placebo stimulation | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Arm A Anodal tDCS and prismatic adaptation | Intervention Type: DEVICE; Name: Control: placebo stimulation; Assigned to Arm(s): Arm B: control
C: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Arm Label: Sham stimulation; Type: SHAM_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Intervention Type: DEVICE; Name: tdcs (ELDITH, Neuroconn, Ilmenau, Germany); Assigned to Arm(s): Real stimulation, Sham stimulation
D: Arm Label: 1- tDCS 2--FES; Type: EXPERIMENTAL; Interventions: Device: Transcranial direct current stimulation (tDCS), Device: Functional electrical stimulation (FES), Device: Sham stimulation | Intervention Type: DEVICE; Name: Transcranial direct current stimulation (tDCS); Assigned to Arm(s): 1- tDCS 2--FES | Intervention Type: DEVICE; Name: Functional electrical stimulation (FES); Assigned to Arm(s): 1- tDCS 2--FES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): 1- tDCS 2--FES

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot™ Ablation System
Brief Summary: The Covidien OneShot™ ablation system use is to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.


Options:
A: Arm Label: Control group; Type: OTHER; Interventions: Procedure: Renal denervation | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Renal denervation | Intervention Type: PROCEDURE; Name: Renal denervation; Assigned to Arm(s): Control group, Intervention group
B: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation (Vessix) | Arm Label: Masked Procedure; Type: SHAM_COMPARATOR; Interventions: Device: Renal Angiography | Intervention Type: DEVICE; Name: Renal Denervation (Vessix); Assigned to Arm(s): Renal Denervation | Intervention Type: DEVICE; Name: Renal Angiography; Assigned to Arm(s): Masked Procedure
C: Arm Label: Rapid Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Covidien OneShot™ System | Intervention Type: DEVICE; Name: Covidien OneShot™ System; Assigned to Arm(s): Rapid Renal Denervation
D: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients
Brief Summary: The goal of this clinical research study is to learn if PCI-32765 (Ibrutinib) combined with rituximab can help to control CLL and SLL. The safety of this combination will also be studied.

Ibrutinib is designed to stop a protein from working in the cells, which may cause the cancer cells to die or stop growing.

Rituximab is designed to attach to cancer cells and damage them, which may cause the cells to die.


Options:
A: Arm Label: Phase I, NHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Phase I, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, iNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 400/400 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1600/800 mg - Phase II, aNHL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: 1000/1000 mg - Phase II, CLL; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Arm Label: Retreated Participants; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): 1000/1000 mg - Phase II, CLL, 1600/800 mg - Phase II, aNHL, 1600/800 mg - Phase II, iNHL, 400/400 mg - Phase II, aNHL, 400/400 mg - Phase II, iNHL, Phase I, CLL, Phase I, NHL, Retreated Participants
B: Arm Label: Fludarabine + Campath-1H; Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab, Drug: fludarabine phosphate | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Fludarabine + Campath-1H | Intervention Type: DRUG; Name: fludarabine phosphate; Assigned to Arm(s): Fludarabine + Campath-1H
C: Arm Label: ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: ofatumumab | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): ofatumumab
D: Arm Label: Rituximab + PCI-32765; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: PCI-32765 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab + PCI-32765 | Intervention Type: DRUG; Name: PCI-32765; Assigned to Arm(s): Rituximab + PCI-32765

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: What Should be the Best Physiotherapy Early After Stroke ?
Brief Summary: This study is designed to observe the respective effects of 2 types of physiotherapy early after a cerebral stroke. The hypothesis is that an intensive physiotherapy early delivered (Day 2 to D15) after a stroke could induce faster motor control recovery than a conservative physiotherapy aiming at preventing complications.


Options:
A: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Robot-Assisted Therapy - MIT-MANUS System | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Comparison Therapy | Arm Label: Arm 3; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Robot-Assisted Therapy - MIT-MANUS System; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Intensive Comparison Therapy; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Arm 3
C: Arm Label: ArmAssist therapy; Type: EXPERIMENTAL; Interventions: Device: ArmAssist robotic training, Other: Conventional therapy | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Arm Label: Extended Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy, Other: Extended conventional therapy | Intervention Type: DEVICE; Name: ArmAssist robotic training; Assigned to Arm(s): ArmAssist therapy | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): ArmAssist therapy, Conventional therapy, Extended Conventional therapy | Intervention Type: OTHER; Name: Extended conventional therapy; Assigned to Arm(s): Extended Conventional therapy
D: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: What Should be the Best Physiotherapy Early After Stroke ?
Brief Summary: This study is designed to observe the respective effects of 2 types of physiotherapy early after a cerebral stroke. The hypothesis is that an intensive physiotherapy early delivered (Day 2 to D15) after a stroke could induce faster motor control recovery than a conservative physiotherapy aiming at preventing complications.


Options:
A: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: Early vertical positioning; Type: ACTIVE_COMPARATOR; Interventions: Other: Mobilization of stroke patients | Arm Label: Progressively vertical positioning; Type: ACTIVE_COMPARATOR; Interventions: Other: Mobilization of stroke patients | Intervention Type: OTHER; Name: Mobilization of stroke patients; Assigned to Arm(s): Early vertical positioning, Progressively vertical positioning
C: Arm Label: The lying flat intervention; Type: EXPERIMENTAL; Interventions: Other: The lying flat (0°) head position for 24 hours | Arm Label: The sitting-up intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: The sitting-up (≥30°) head position for 24 hours | Intervention Type: OTHER; Name: The lying flat (0°) head position for 24 hours; Assigned to Arm(s): The lying flat intervention | Intervention Type: OTHER; Name: The sitting-up (≥30°) head position for 24 hours; Assigned to Arm(s): The sitting-up intervention
D: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy

Answer: D